Escient Pharmaceuticals Inc
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2022 | $60 M | No. 3 | $50 to $250 million | equity | SEC | |
| Aug 2020 | $39 M | No. 2 | $10 to $50 million | equity | SEC | |
| Mar 2018 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Escient Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Nov 2022).
SEC Form D · Nov 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2022
That is all the official record says: Escient Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Escient Pharmaceuticals Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Aaron Sereda Mishel | Executive officer | Nov 2022 |
| Joshua Grass | Executive officer | Nov 2022 |
| Marcus Boehm | Executive officer | Nov 2022 |
| Alain Baron | Executive officer | Sep 2020 |
| Andrew Sereda Schwab | Director | Nov 2022 |
| Charles Sereda Zuker | Director | Nov 2022 |
| Jason Sereda Hafler | Director | Nov 2022 |
| JeenJoo Sereda Kang | Director | Nov 2022 |
| Joshua Grass | Director | Nov 2022 |
| Kathleen Sereda Glaub | Director | Nov 2022 |
| Kevin Sereda Raidy | Director | Nov 2022 |
| Peter Sereda Hirth | Director | Nov 2022 |
| Alain Baron | Director | Sep 2020 |
| Andrew Schwab | Director | Sep 2020 |
| Charles Zuker | Director | Sep 2020 |
| Jason Hafler | Director | Sep 2020 |
| JeenJoo Kang | Director | Sep 2020 |
| Kathleen Glaub | Director | Sep 2020 |
| Kevin Raidy | Director | Sep 2020 |
| Peter Hirth | Director | Sep 2020 |
| Robert Tjian | Director | Apr 2018 |